Skip to main content

Table 2 Summary of measurements at baseline (pre-CRRT)

From: Effects of regional citrate anticoagulation on thrombin generation, fibrinolysis and platelet function in critically ill patients receiving continuous renal replacement therapy for acute kidney injury: a prospective study

Investigations Units Reference range Number with abnormal results Range of abnormal results Mean/median
Thrombin time Ratio (0.86–1.14) 1 1.19 N/A
Classic APCR Ratio (3.3–5.82) 3 2.22, 2.25, 2.44 2.30/2.25
Modified APCR Ratio (2.63–3.34) 3 1.81,2.51, 2.53 2.28/2.51
Antithrombin activity IU/dL (85.9–117.5) 9 24.2–80.0 61.8/67.4
Protein C activity IU/dL (77.1–126.4) 9 38.5–72.5 58.3/61.5
Free protein S antigen IU/dL (80.2–137.4) 5 48.9–76.2 67.7/70.4
Lupus anticoagulant by dRVVT and dAPTT - Not detected 5 5 × positive N/A
IgG aCL GPL U/mL (0–10) 3 11.2, 13.5, 17.2 14.0/13.5
IgM aCL MPL U/mL (0–10) 3 19.2, 19.7, 31.9 23.6/19.7
IgG aβ2GPI SGU (0–2.9) 3 3.9, 6.0, 8.6 6.2/6.0
IgM aβ2GPI SMU (0–6.5) 7 6.8–31.9 15.0/12.0
Homocysteine µmol/L (0–15) 5 15.2–18.0 16.1/15.6
VWF:GPIbR IU/dL (41–127) 4 380.1–494.1 426.0/415.0
VWF:Ag IU/dL (50–172) 11 280.8–682.7 531.3/581.3
FVIII:C IU/dL (50–150) 11 199.4–614.4 418.4/432.6
Thrombin:antithrombin complexes (TAT) µg/L (1–4.1) 7 9.22–74.6 24.3/25.1
Prothrombin fragment 1.2 pmol/L (69–229) 3 333.3, 401.1, 964.0 566.1/401.1
Prothrombin 20,210 1 1 × heterozygous N/A
Factor V Leiden 0
  1. aβ2GPI anti-β2 glycoprotein I antibodies, aCL anticardiolipin antibodies, APCR activated protein C resistance, dAPTT dilute activated partial thromboplastin time, dRVVT dilute Russell’s viper venom time, FVIII:C factor VIII coagulant activity assay, VWF:GPIbR ristocetin-triggered von Willebrand factor glycoprotein Ib-binding activity assay, VWF:Ag von Willebrand factor antigen